Program of vascular evaluation under uric acid control by xanthine oxidase inhibitor, febuxostat: multicenter, randomized controlled study
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Febuxostat (Primary)
- Indications Hyperuricaemia
- Focus Pharmacodynamics
- Acronyms PRIZE
- 29 Mar 2023 Results of a subanalysis of the PRIZE study (n=383) assessing the effect of febuxostat on the level of malondialdehyde-modified low-density lipoprotein (MDA-LDL), an oxidative stress marker, published in the Clinical Cardiology.
- 01 Apr 2022 Results of subanalysis comparing the long-term effects of febuxostat on atherosclerosis and arterial stiffness, published in the Hypertension Research
- 11 Aug 2020 Status changed from active, no longer recruiting to completed.